Bhubaneswar: India’s indigenous COVID-19 vaccine Covaxin reportedly faced an adverse incident during its Phase I trial back in August. The company claims that it reported the incident within 24 hours.
“The adverse event during Phase I clinical trials in August 2020 was reported to the CDSCO-DCGI, within 24 hours of its occurrence and confirmation,” Bharat Biotech said in a statement on Saturday.
The Hyderabad-based firm is working with ICMR to produce the vaccine which has now received approval for Phase III trials.
The vaccine is being tested at 21 medical institutes in the country, including IMS & SUM Hospital in Bhubaneswar.
“The adverse event was investigated thoroughly, and presented to the CDSCO-DCGI, prior to obtaining permission for Phase II and Phase III clinical trials,” said Bharat Biotech.
New Delhi: Accused of giving cash to secure votes ahead of election day in Maharashtra,…
Bhubaneswar: Chief Minister Mohan Charan Majhi attended the ‘Odisha State Day Celebrations’ at the 43rd…
Mumbai: Recently, some morphed pictures of actress Shweta Tiwari and her good friend Vishal Aditya…
Phulbani: Two tribal men were sentenced to life imprisonment by a special court in Odisha's…
New Delhi: It’s been just over two months since Atishi took oath as Delhi’s chief…
Bhubaneswar: In a moment of pride for AIIMS Bhubaneswar, Dr Manita Tamang, a final-year Senior…
Imphal: In view of the surge in violence in troubled Manipur, the Central government will send…
New Delhi/Bhubaneswar: The 7th edition of Odisha Parba got off to a colourful start in…